Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as A: Epinephrine injection
A: Epinephrine · 1 trial · 2 indications
Plasma level of Epinephrine
Pharmacodynamic response
Pharmacodynamic response
Pharmacodynamic response
| Arm | Type | Description |
|---|---|---|
| 6 Healthy volunteers, sequence ABC | EXPERIMENTAL | Three drug administrations to each subject, each administration on a separate day. treatment order: A B C |
| 6 Healthy volunteers, sequence BAC | EXPERIMENTAL | Three drug administrations to each subject, each administration on a separate day. treatment order: B A C |
| Name | Type | Description |
|---|---|---|
| A: Epinephrine injection | DRUG | Autoinjector for intramuscular, single-use, 0.3mg |
| B: FMXIN002 3.6mg | DRUG | Nasus Pharma nasal powder spray 3.6 mg, single use in one nostril |
| C: FMXIN002 4.0mg | DRUG | Nasus Pharma nasal powder spray 4.0 mg, single use in one nostril |
Inclusion Criteria: * 1\) Non-smoking, male and female subjects from 18 to 55 years of age. 2) BMI ≥18 \< 30 kg/m2. 3) Females may be of childbearing or non-childbearing potential: * Childbearing potential: o Physically capable of becoming pregnant, must be willing to use acceptable effecti...
A: Epinephrine is being developed for anaphylaxis, a severe and potentially life-threatening allergic reaction. It is an investigational small molecule in Phase 1 development by Nasus Pharma Ltd. The completed Phase 1 trial enrolled healthy adult volunteers to study the drug rather than patients experiencing anaphylaxis.
A: Epinephrine is being developed by Nasus Pharma Ltd., which trades under the ticker NSRX. The company is advancing the asset as an investigational small molecule for anaphylaxis within the immunology therapeutic area. Development is currently at the Phase 1 stage, with one completed clinical trial and no active trials.
A: Epinephrine is in Phase 1 development. Nasus Pharma Ltd. has completed one Phase 1 trial of the investigational small molecule, and no trials are currently active. The program has not been approved by the FDA and remains in clinical development for anaphylaxis.
A: Epinephrine has been studied in one completed Phase 1 trial, NCT06205134, titled Comparative Bioavailability of Intranasal Epinephrine. The trial enrolled 12 healthy adult volunteers in Israel, used a randomized controlled design, and included both male and female participants aged 18 years and older. No trials are currently active.
A: Epinephrine injection is another name used for A: Epinephrine, the investigational small molecule developed by Nasus Pharma Ltd. for anaphylaxis. The completed Phase 1 trial NCT06205134 evaluated an intranasal formulation of epinephrine in 12 healthy adult volunteers in Israel.